{"id":"switch","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["ziprasidone"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"_scrapedAt":"2026-03-28T00:32:46.959Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Switch","title":"Switch","extract":"In electrical engineering, a switch is an electrical component that can disconnect or connect the conducting path in an electrical circuit, interrupting the electric current or diverting it from one conductor to another. The most common type of switch is an electromechanical device consisting of one or more sets of movable electrical contacts connected to external circuits. When a pair of contacts is touching, current can pass between them, while the contacts are separated no current can flow."},"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07435077","phase":"PHASE4","title":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":282},{"nctId":"NCT03188900","phase":"","title":"Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-12","conditions":"Preeclampsia","enrollment":236},{"nctId":"NCT06389136","phase":"PHASE3","title":"A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-06-14","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT04958265","phase":"PHASE3","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-11-17","conditions":"Atypical Hemolytic Uremic Syndrome","enrollment":41},{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT05630781","phase":"NA","title":"Orexin s Role in the Neurobiology of Substance Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-02-15","conditions":"Nicotine Dependence","enrollment":140},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT06441305","phase":"NA","title":"Expanding Coverage of Severe Acute Malnutrition (SAM) Treatment in Kenya","status":"RECRUITING","sponsor":"International Food Policy Research Institute","startDate":"2024-06-03","conditions":"Acute Malnutrition, Severe, Malnutrition, Child, Wasting","enrollment":1600},{"nctId":"NCT06380504","phase":"NA","title":"Increasing the Coverage of Severe Acute Malnutrition (SAM) Treatment in Ethiopia","status":"RECRUITING","sponsor":"International Food Policy Research Institute","startDate":"2024-05-02","conditions":"Acute Malnutrition, Severe, Malnutrition, Child, Wasting","enrollment":1080},{"nctId":"NCT04886999","phase":"PHASE3","title":"Study in Adult Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-24","conditions":"Asthma","enrollment":78},{"nctId":"NCT06732245","phase":"PHASE2","title":"Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese","status":"NOT_YET_RECRUITING","sponsor":"Biomed Industries, Inc.","startDate":"2026-08-15","conditions":"Obesity and Overweight","enrollment":224},{"nctId":"NCT07414394","phase":"PHASE3","title":"Tigulixostat (IBI128) vs Febuxostat in Gout","status":"RECRUITING","sponsor":"Innovent Biologics Technology Limited (Shanghai R&D Center)","startDate":"2026-03-17","conditions":"Gout","enrollment":600},{"nctId":"NCT07492628","phase":"PHASE1","title":"Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-03-02","conditions":"Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma","enrollment":42},{"nctId":"NCT07491718","phase":"NA","title":"Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-08-08","conditions":"Takotsubo Cardiomyopathy","enrollment":100},{"nctId":"NCT05685238","phase":"PHASE3","title":"A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2023-02-13","conditions":"Haemophilia A, Haemophilia A With Inhibitors","enrollment":451},{"nctId":"NCT07489677","phase":"NA","title":"The Feasibility and Acceptability of a Collaborative Deprescribing Intervention to Reduce Anticholinergic Burden Among Hospitalised Older Patients","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2025-05-22","conditions":"Older Adults (60 - 85 Years Old)","enrollment":21},{"nctId":"NCT07006506","phase":"PHASE2","title":"A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-21","conditions":"Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy","enrollment":46},{"nctId":"NCT07151690","phase":"PHASE2","title":"BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-04","conditions":"Systemic Light Chain Amyloidosis","enrollment":21},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT05421858","phase":"PHASE3","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","status":"RECRUITING","sponsor":"Basilea Pharmaceutica","startDate":"2024-12-11","conditions":"Candidemia, Candidiasis, Invasive","enrollment":450},{"nctId":"NCT06158139","phase":"PHASE1","title":"Autologous CAR-T Cells Targeting B7-H3 in PDAC","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-07-18","conditions":"Pancreas Cancer, Relapse, Resistant Cancer","enrollment":27},{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT06751992","phase":"PHASE4","title":"Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-17","conditions":"Kidney Transplant Recipients, Old Age","enrollment":92},{"nctId":"NCT05808036","phase":"NA","title":"Efficacy of the DOMINO Diet App in IBS","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-04-01","conditions":"Irritable Bowel Syndrome","enrollment":110},{"nctId":"NCT05373758","phase":"NA","title":"A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-02-07","conditions":"HIV Infections, AIDS, Virologic Failure","enrollment":648},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT07288437","phase":"NA","title":"Deep Brain Stimulation for Spinocerebellar Ataxia","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03","conditions":"Spinocerebellar Ataxia (SCA), Spinocerebellar Ataxia Type 6","enrollment":5},{"nctId":"NCT07476846","phase":"NA","title":"rhTPO Dose Escalation vs Eltrombopag Switch in ITP","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":112},{"nctId":"NCT07478224","phase":"NA","title":"An Interventional Study to Evaluate the Impact of Blood Flow Restriction Training on Muscle, Bone, and Quality of Life in Adults With Osteogenesis Imperfecta Type I","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-08-19","conditions":"Osteogenesis Imperfecta, Type I","enrollment":40},{"nctId":"NCT05438043","phase":"PHASE3","title":"A Study of Daratumumab","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-15","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT07290803","phase":"","title":"This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-11-17","conditions":"Atopic Dermatitis","enrollment":1000},{"nctId":"NCT03883217","phase":"NA","title":"Optimizing Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2021-06-29","conditions":"Parkinson Disease","enrollment":12},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT04108208","phase":"PHASE4","title":"A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-17","conditions":"Prostatic Neoplasms","enrollment":75},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT07449234","phase":"","title":"A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis","status":"RECRUITING","sponsor":"Janssen-Cilag Ltd.","startDate":"2026-02-09","conditions":"Psoriasis","enrollment":200},{"nctId":"NCT05797610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-08-08","conditions":"Primary IgA Nephropathy","enrollment":428},{"nctId":"NCT04960579","phase":"PHASE1","title":"P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma","status":"RECRUITING","sponsor":"Poseida Therapeutics, Inc.","startDate":"2022-05-05","conditions":"Multiple Myeloma","enrollment":275},{"nctId":"NCT06947538","phase":"NA","title":"Stepped Care for Posttraumatic Stress Disorder Study","status":"RECRUITING","sponsor":"Boston Medical Center","startDate":"2026-03-12","conditions":"Post Traumatic Stress Disorder","enrollment":428},{"nctId":"NCT06898203","phase":"NA","title":"Precision Imaging to Evaluate Kaposi Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-05-31","conditions":"Kaposi Sarcoma","enrollment":300},{"nctId":"NCT07471139","phase":"PHASE3","title":"SWITCH: Apixaban vs Vitamin K in HM3","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-06","conditions":"LVAD (Left Ventricular Assist Device) Thrombosis, Heart Failure, Bleeding","enrollment":460},{"nctId":"NCT06425549","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-06-25","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":168},{"nctId":"NCT06881251","phase":"PHASE2","title":"A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-02-26","conditions":"Dermatitis, Atopic","enrollment":256},{"nctId":"NCT07217587","phase":"PHASE3","title":"Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-01-05","conditions":"Myasthenia Gravis","enrollment":115},{"nctId":"NCT05347095","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen-Cilag Ltd.","startDate":"2022-09-27","conditions":"Fistulizing Crohns Disease, Perianal Crohns Disease","enrollment":288},{"nctId":"NCT06663332","phase":"PHASE3","title":"A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-29","conditions":"Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic","enrollment":196},{"nctId":"NCT07230860","phase":"PHASE2","title":"A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-01-20","conditions":"Dermatitis, Atopic","enrollment":180},{"nctId":"NCT06854094","phase":"","title":"Consolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ente Ospedaliero Cantonale, Bellinzona","startDate":"2024-10-03","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT07467863","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC","enrollment":48},{"nctId":"NCT06372899","phase":"NA","title":"Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2024-10-02","conditions":"E-cigarette Use, Cigarette Smoking, Harm Reduction","enrollment":200},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT06382207","phase":"NA","title":"Effectiveness of the Eko Digital Stethoscope in Capturing Infant ECGs","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-01-17","conditions":"Tachyarrhythmia","enrollment":100},{"nctId":"NCT07465666","phase":"","title":"A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-04-01","conditions":"Hypertension","enrollment":500},{"nctId":"NCT07452757","phase":"NA","title":"To Evaluate Efficacy and Safety of Proprietary Healthy Diet Combinations for Weight Management in Overweight Volunteers","status":"COMPLETED","sponsor":"Bioagile Therapeutics Pvt. Ltd.","startDate":"2023-11-15","conditions":"Overweight (BMI > 25)","enrollment":140},{"nctId":"NCT07416526","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-05-09","conditions":"Hemophilia A","enrollment":126},{"nctId":"NCT07264361","phase":"NA","title":"Evaluation of the Safety and Efficacy of the D.D.C Dual-control Technology Spectacle Lenses in Delaying the Progression of Myopia: a Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2026-03-30","conditions":"Myopia, Progressive","enrollment":316},{"nctId":"NCT05359653","phase":"PHASE1, PHASE2","title":"Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-08-01","conditions":"Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive","enrollment":74},{"nctId":"NCT06065670","phase":"PHASE1, PHASE2","title":"Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-09-15","conditions":"Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion","enrollment":44},{"nctId":"NCT07416604","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-04-30","conditions":"Hemophilia A","enrollment":360},{"nctId":"NCT07462637","phase":"NA","title":"Signature Response to Light Therapy in Unipolar and Bipolar Major Depressive Episode (MDE)","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-03-01","conditions":"Major Depressive Episode","enrollment":173},{"nctId":"NCT07180550","phase":"NA","title":"Acute Effects of High-intensity Interval Aerobic and Functional Training at Different Intensities","status":"RECRUITING","sponsor":"European University Miguel de Cervantes","startDate":"2025-10-12","conditions":"High Intensity Interval Training (Cycling), High Intensity Interval Training (Running), High Intensity Functional Training","enrollment":27},{"nctId":"NCT05147220","phase":"PHASE3","title":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-16","conditions":"Relapsing Multiple Sclerosis","enrollment":1001},{"nctId":"NCT07462650","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-01","conditions":"Colorectal Cancer Metastatic, Adenocarcinoma of Colon","enrollment":48},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT06551519","phase":"","title":"A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-28","conditions":"Multiple Sclerosis","enrollment":700},{"nctId":"NCT07457359","phase":"PHASE2","title":"Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-04","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":18},{"nctId":"NCT05681702","phase":"PHASE4","title":"Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI","status":"RECRUITING","sponsor":"University of Florida","startDate":"2023-02-15","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT07454837","phase":"PHASE2, PHASE3","title":"Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide","status":"RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2026-02-26","conditions":"Chronic Hepatitis D","enrollment":120},{"nctId":"NCT06700343","phase":"PHASE3","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-01-13","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":444},{"nctId":"NCT06118502","phase":"NA","title":"A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2024-03-25","conditions":"Cigarette Smoking, Smoking Behaviors, Treatment","enrollment":544},{"nctId":"NCT04877522","phase":"PHASE4","title":"Asciminib Roll-over Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-30","conditions":"Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive","enrollment":347},{"nctId":"NCT07379827","phase":"","title":"Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-26","conditions":"Schizophrenia","enrollment":1500},{"nctId":"NCT07455188","phase":"","title":"A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-03-01","conditions":"Breast Cancer","enrollment":600},{"nctId":"NCT07169747","phase":"PHASE2","title":"Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa","status":"RECRUITING","sponsor":"Region Skane","startDate":"2026-04-20","conditions":"Anorexia Nervosa","enrollment":40},{"nctId":"NCT07128550","phase":"PHASE3","title":"A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide","status":"RECRUITING","sponsor":"Vir Biotechnology, Inc.","startDate":"2025-07-30","conditions":"Viral Hepatitis","enrollment":150},{"nctId":"NCT03859713","phase":"NA","title":"Optimize Low Back Pain","status":"COMPLETED","sponsor":"University of Utah","startDate":"2019-03-22","conditions":"Low Back Pain, Chronic Pain","enrollment":749},{"nctId":"NCT04805502","phase":"NA","title":"Pregnancy Exercise Mode Effect on Childhood Obesity","status":"RECRUITING","sponsor":"East Carolina University","startDate":"2021-10-18","conditions":"Pregnancy, Overweight and Obesity","enrollment":300},{"nctId":"NCT06923111","phase":"","title":"PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]","status":"RECRUITING","sponsor":"Nova Laboratories Limited","startDate":"2025-06-09","conditions":"Sickle Cell Disease","enrollment":180},{"nctId":"NCT05816382","phase":"PHASE2, PHASE3","title":"A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions","status":"RECRUITING","sponsor":"Takeda","startDate":"2023-04-05","conditions":"Narcolepsy Type 1","enrollment":500},{"nctId":"NCT06715306","phase":"NA","title":"Intravenous Versus Oral Treatment of the Main Acute Infections","status":"RECRUITING","sponsor":"University of Southern Denmark","startDate":"2025-01-15","conditions":"Respiratory Tract Infections, Urinary Tract Infections, Cellulitis","enrollment":4000},{"nctId":"NCT07287150","phase":"PHASE2","title":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":100},{"nctId":"NCT03741127","phase":"PHASE1","title":"Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101","status":"ACTIVE_NOT_RECRUITING","sponsor":"Poseida Therapeutics, Inc.","startDate":"2018-10-29","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT06626334","phase":"NA","title":"Blue Light as an Anti-inflammatory and Analgesic Strategy in Thoracic Trauma","status":"RECRUITING","sponsor":"Rebecca E Kotcher, MD","startDate":"2024-10-23","conditions":"Rib Fractures, Pain, Acute","enrollment":75},{"nctId":"NCT05993767","phase":"PHASE2","title":"UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2024-12-11","conditions":"HIV Infection","enrollment":53},{"nctId":"NCT07448324","phase":"PHASE2","title":"Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-01","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":50},{"nctId":"NCT06922617","phase":"NA","title":"STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-10-17","conditions":"Tobacco Use, Substance Use Disorders","enrollment":240},{"nctId":"NCT06398106","phase":"PHASE4","title":"Proactive TDM Versus Standard Use of Biologics in Psoriasis","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2024-12-20","conditions":"Psoriasis Vulgaris","enrollment":210},{"nctId":"NCT07445425","phase":"NA","title":"Comparison of Radiofrequency Ablation With Concomitant or Staged Treatment for Tributary Varicose Veins","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2026-03","conditions":"Varicose Veins of Lower Limb","enrollment":206},{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease","enrollment":100},{"nctId":"NCT07007195","phase":"EARLY_PHASE1","title":"Smart Olfaction App to Reduce Relapse","status":"NOT_YET_RECRUITING","sponsor":"University of Houston","startDate":"2026-03-23","conditions":"Nicotine Dependence","enrollment":132},{"nctId":"NCT06101342","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":181},{"nctId":"NCT06801327","phase":"NA","title":"Comparison Between Conventional Respiratory Physiotherapy and the Simeox Device in Patients With Bronchiectasis","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2024-12-01","conditions":"Bronchiectasis Adult","enrollment":40},{"nctId":"NCT05301608","phase":"PHASE1, PHASE2","title":"Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2022-03-03","conditions":"Healthy","enrollment":30},{"nctId":"NCT03683251","phase":"PHASE3","title":"Extension Study for the Port Delivery System With Ranibizumab (Portal)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-09-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1000},{"nctId":"NCT07304180","phase":"NA","title":"Exergame vs Balance Training in Hemiplegia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Halic University","startDate":"2025-12-16","conditions":"Hemiplegia, Exergaming, Exercise","enrollment":30},{"nctId":"NCT07276373","phase":"PHASE1, PHASE2","title":"Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Corcept Therapeutics","startDate":"2026-01-16","conditions":"Neoplasms","enrollment":50},{"nctId":"NCT04093323","phase":"PHASE2","title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-11-13","conditions":"HLA-A2 Positive Cells Present, Refractory Melanoma","enrollment":1},{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT06588595","phase":"PHASE4","title":"The Switching Antiplatelet-9 (SWAP-9) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-11-01","conditions":"Coronary Arterial Disease (CAD)","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":106981,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Switch","genericName":"Switch","companyName":"Dartmouth-Hitchcock Medical Center","companyId":"dartmouth-hitchcock-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":9,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}